Targeted therapies and immunotherapy in non-small-cell lung cancer
نویسندگان
چکیده
منابع مشابه
Targeted therapies and immunotherapy in non-small-cell lung cancer
Non-small-cell lung cancer is still considered a difficult disease to manage because of its aggressiveness and resistance to common therapies. Chemotherapy remains the gold standard in nearly 80% of lung cancers, but clinical outcomes are discouraging, and the impact on median overall survival (OS) barely reaches 12 months. At the end of the last century, the discovery of oncogene-driven tumour...
متن کاملNon-small-cell lung cancer: targeted therapies
Chemotherapy: is it still enough? The major progresses in understanding cancer biology and the mechanism of oncogenesis have allowed the development of several potential molecular target drugs for cancer treatment, which are components of signaling pathways or metabolic processes contributing to the acquisition of cancer phenotype. A general better tolerability, owing to a milder toxicity profi...
متن کاملImmunotherapy and Targeted Therapies in the Treatment of Non-small Cell Lung Cancer
I n the last decade, the emergence of targeted therapies has changed the treatment paradigm for non-small cell lung cancer (NSCLC). The growing availability of therapies targeting specific genetic alterations, such as epidermal growth factor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements, have led to changes in the guidelines to reflect the need for molecular profiling. Mo...
متن کاملMulti-Targeted Therapies in Non-Small Cell Lung Cancer
E-mail: [email protected] Tel (Fax): 86-22-2352 2919 ABSTRACT Current treatment modalities provide limited improvement in the natural course of lung cancer, and prognosis remains poor. Lung cancer is a malignancy with great molecular heterogeneity. The complexity of the signaling process leading to cancer cell proliferation and to the neoplastic phenotype supports the necessity of interferi...
متن کاملCombination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
Treatment for advanced non-small cell lung cancer (NSCLC) has been significantly improved in recent years with the incorporation of drugs targeting antiangiogenesis and more specifically genomic alterations such as the EGFR mutations and ALK translocations. However, most patients invariably progress and die. The emergence of immune checkpoint inhibitors targeting the pathways involved in tumor-...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: ecancermedicalscience
سال: 2016
ISSN: 1754-6605
DOI: 10.3332/ecancer.2016.648